Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence.

Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, McBride W, Tso CL.

PLoS One. 2013 Nov 18;8(11):e80397. doi: 10.1371/journal.pone.0080397. eCollection 2013.

2.

Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.

Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, Soroceanu L.

Cell Death Dis. 2015 Jan 15;6:e1601. doi: 10.1038/cddis.2014.566.

3.

Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.

Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, Bui Y, Stream A, McBride WH, Liau LM, Nelson SF, Cloughesy TF, Yong WH, Lai A, Tso CL.

Mol Cancer. 2015 Nov 6;14:189. doi: 10.1186/s12943-015-0459-1.

4.

MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.

Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K, Watanabe E, Tachibana K, Tomiyama A, Kayama T, Kitanaka C.

Stem Cells. 2011 Dec;29(12):1942-51. doi: 10.1002/stem.753.

5.

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.

Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M.

J Neurochem. 2012 Jul;122(2):444-55. doi: 10.1111/j.1471-4159.2012.07781.x. Epub 2012 May 28.

6.

Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.

Yong WH, Shabihkhani M, Telesca D, Yang S, Tso JL, Menjivar JC, Wei B, Lucey GM, Mareninov S, Chen Z, Liau LM, Lai A, Nelson SF, Cloughesy TF, Tso CL.

PLoS One. 2015 Oct 27;10(10):e0141334. doi: 10.1371/journal.pone.0141334. eCollection 2015.

7.

YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.

Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K.

Oncol Rep. 2014 Jul;32(1):159-66. doi: 10.3892/or.2014.3195. Epub 2014 May 16.

PMID:
24842123
8.

Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.

Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW.

Cancer Res. 2011 Mar 15;71(6):2308-17. doi: 10.1158/0008-5472.CAN-10-3213.

9.

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L.

Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.

10.

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.

Tentori L, Ricci-Vitiani L, Muzi A, Ciccarone F, Pelacchi F, Calabrese R, Runci D, Pallini R, Caiafa P, Graziani G.

BMC Cancer. 2014 Mar 5;14:151. doi: 10.1186/1471-2407-14-151.

11.

Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.

Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, Kiss R, Lefranc F.

Neoplasia. 2010 Sep;12(9):727-39. Erratum in: Neoplasia. 2011 Sep;13(9):5 p following 886.

12.

Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.

Riccitelli E, Giussani P, Di Vito C, Condomitti G, Tringali C, Caroli M, Galli R, Viani P, Riboni L.

PLoS One. 2013 Jun 24;8(6):e68229. doi: 10.1371/journal.pone.0068229. Print 2013.

13.

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.

Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN.

Clin Cancer Res. 2009 Jul 15;15(14):4622-9. doi: 10.1158/1078-0432.CCR-08-3012. Epub 2009 Jul 7. Erratum in: Clin Cancer Res. 2013 Aug 15;19(16):4543-4.

14.

Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis.

Hiddingh L, Raktoe RS, Jeuken J, Hulleman E, Noske DP, Kaspers GJ, Vandertop WP, Wesseling P, Wurdinger T.

Sci Rep. 2014 Jun 11;4:5260. doi: 10.1038/srep05260.

15.

TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.

Loftus JC, Dhruv H, Tuncali S, Kloss J, Yang Z, Schumacher CA, Cao B, Williams BO, Eschbacher JM, Ross JT, Tran NL.

Mol Cancer Res. 2013 Aug;11(8):865-74. doi: 10.1158/1541-7786.MCR-13-0008. Epub 2013 May 22.

16.

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.

Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.

Cancer Lett. 2013 Apr 30;331(1):68-75. doi: 10.1016/j.canlet.2012.12.005. Epub 2012 Dec 12.

PMID:
23246370
17.

c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.

Luo H, Chen Z, Wang S, Zhang R, Qiu W, Zhao L, Peng C, Xu R, Chen W, Wang HW, Chen Y, Yang J, Zhang X, Zhang S, Chen D, Wu W, Zhao C, Cheng G, Jiang T, Lu D, You Y, Liu N, Wang H.

Brain. 2015 Dec;138(Pt 12):3654-72. doi: 10.1093/brain/awv287. Epub 2015 Oct 8.

PMID:
26450587
18.

MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.

Zhang S, Wan Y, Pan T, Gu X, Qian C, Sun G, Sun L, Xiang Y, Wang Z, Shi L.

J Mol Neurosci. 2012 Jun;47(2):346-56. doi: 10.1007/s12031-012-9759-8. Epub 2012 Apr 19.

PMID:
22528454
19.

Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.

Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D.

Neuro Oncol. 2013 Nov;15(11):1502-17. doi: 10.1093/neuonc/not104. Epub 2013 Jul 28.

20.

MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.

Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis RM, Hargrave D, Workman P, Jones C.

Cancer Res. 2010 Nov 15;70(22):9243-52. doi: 10.1158/0008-5472.CAN-10-1250. Epub 2010 Oct 8.

Items per page

Supplemental Content

Write to the Help Desk